Navigation Links
Pharmasset Reports First Fiscal Quarter 2008 Financial Results

ated potent anti-HCV activity.

Anticipated Highlights

-- Oral presentation of the final safety and efficacy data from two

cohorts from the third part of a Phase 1 study of R7128 following 4

weeks of combination therapy with Pegasys plus Copegus at the 43rd

Annual Meeting of the European Association for the Study of the Liver

(EASL) being held from April 23-27, 2008 in Milan, Italy.

-- Complete HBV patient enrollment for clevudine Phase 3 registration

clinical trials in the second calendar half of 2008.

-- Initiate HCV patient screening for a 12-week Phase 2b combination

study of R7128 with Pegasys plus Copegus in the fourth calendar

quarter of 2008, assuming the successful completion of the on-going

R7128 Phase 1 study, transfer of our IND for R7128 to Roche, consent

from the FDA and timely completion of all required Phase 2b study

preparation activities.

-- Conducting preclinical studies of a proprietary anti-HCV nucleoside

analog to support first-in-human clinical trials, once a lead compound

has been nominated from the series.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
2. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
3. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. CEL-SCI Corporation Reports First Quarter Financial Results
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
11. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ... from Hercules Technology Growth Capital, Inc. (NYSE: ... final advance under the Loan and Security Agreement that ... , Alimera Sciences Limited, entered into with Hercules in ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... Planet Biopharmaceuticals, Inc. and its wholly owned Subsidiaries ... on providing products for allergy and asthma sufferers, today ... ALLERGY CONTROL PRODUCTS, INC., a Delaware corporation("ACP") to RH ... Theron E. Odlaug, Ph. D., CEO and ...
... Communication efforts on behalf of the public and private healthcare ... are today, according to a new book , "Health ... Nancy J. Hicks and Christina Mazzola Nicols of Ketchum ... The book, released this fall from Jones & ...
Cached Medicine Technology:New Book Highlights Opportunities for Healthcare Industry Communications 2New Book Highlights Opportunities for Healthcare Industry Communications 3New Book Highlights Opportunities for Healthcare Industry Communications 4New Book Highlights Opportunities for Healthcare Industry Communications 5
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... find life insurance for senior citizens. , Senior ... Agencies will now sell coverage to seniors who are ... can be purchased without taking a medical examination. , ... purchased online and senior clients can qualify. Having life ...
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
(Date:10/1/2014)... Join the more than 80 golfers who already have ... charity golf tournament to benefit Project HEAL, a not-for-profit organization ... afford treatment. The tournament will be held Monday, Oct. 6, ... The day-long event starts with 10:30 a.m. check-in and shotgun ... begin at 5 p.m. and will include an auction featuring ...
(Date:10/1/2014)... Kennebunkport, Maine (PRWEB) October 01, 2014 ... autoimmune disorders in the U.S., according to figures from ... Autoimmune Related Diseases Association (AARDA), and many of them ... higher chance of having undiagnosed celiac disease. Gluten ... helping raise awareness of undiagnosed celiac disease by publishing ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... have to drink more to feel drunk than non-smoking ... their brains, livers and hearts, a new study suggests. ... rats, which are considered a good model for humans.Since alcohol ... more alcohol to get an expected level of intoxication, say ...
... study of the similarities and differences in disease patterns in ... We share many of our genes with our primate cousins ... similar in many ways, but dogs do not suffer from ... ,Professor Bob Michell is Professor of Comparative Medicine at ...
... a lot of drug-company money to tell doctors not to ... makes sense to involve the industry in a campaign that's ... unethical behavior. // ,At issue are the ... and trips, that some drug makers shower on doctors. Ethicists ...
... your genes, and everything to do with your upbringing say UK ... believed to be at least partly genetically determined - so researchers ... team asked 71 pairs of identical twins and 56 pairs of ... on a scale of 0 to 10.// A zero deemed the ...
... genome sequence suggests a route to new antibiotics, and ... even minor infections can become a major threat. There ... resistant bacteria.// ,Antibiotic resistance is a growing public ... from the soil bacteria Streptomyces , including erthyromycin and ...
... the Study of Aging and the International Longevity Center says ... advised to put down the pill bottle and pick up ... crossword puzzles, exercise and seek help for emotional problems may ... unproven cures such as melatonin, DHEA, testosterone and human growth ...
Cached Medicine News:
... Strep A Test is a color immunochromatographic ... uses antibody labeled color particles coated at ... DLT allows greater sensitivity than the conventional ... the test procedure, a throat swab is ...
... The IntraLase FS laser introduces new high ... Surgeons now have the opportunity to offer ... to a microkeratome for creating the corneal ... FS laser and proprietary IntraLASIK software, surgeons ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
... term complications associated with diabetes continue to ... and quality of life of patients, in ... complications are known to be associated with ... that the level of haemoglobin A1c (HbA1c) ...
Medicine Products: